RepTB: a gene ontology based drug repurposing approach for tuberculosis.

Tuberculosis (TB) is the world's leading infectious killer with 1.8 million deaths in 2015 as reported by WHO. It is therefore imperative that alternate routes of identification of novel anti-TB compounds are explored given the time and costs involved in new drug discovery process.

Resources, challenges and way forward in rare mitochondrial diseases research.

Over 300 million people are affected by about 7000 rare diseases globally. There are tremendous resource limitations and challenges in driving research and drug development for rare diseases. Hence, innovative approaches are needed to identify potential solutions.

BioPhytMol: a drug discovery community resource on anti-mycobacterial phytomolecules and plant extracts.

Background: Tuberculosis (TB) is the second leading cause of death from a single infectious organism, demanding attention towards discovery of novel anti-tubercular compounds. Natural products or their derivatives have provided more than 50% of all existing drugs, offering a chemically diverse space for discovery of novel drugs.

Description: BioPhytMol has been designed to systematically curate and analyze the anti-mycobacterial natural product chemical space.